The risk of deep venous thrombosis with oral contraceptives containing drospirenone

BMJ 2011; 342 doi: http://dx.doi.org/10.1136/bmj.d2519 (Published 21 April 2011)
Cite this as: BMJ 2011;342:d2519

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Nick Dunn, senior lecturer in medical education
  1. 1Faculty of Medicine, University of Southampton, Southampton SO17 1BJ, UK
  1. nick.dunn{at}soton.ac.uk

Data are inconclusive, but alternatives may be preferable unless specifically contraindicated

Drospirenone is a synthetic progestogen, derived from the aldosterone blocker spironolactone. It is structurally related to progesterone and has antiandrogenic and anti-mineralocorticoid properties. It has been marketed in oral contraceptive preparations, combined with 30 mg of ethinylestradiol, since about 2000. The contraceptive efficacy of such pills is undoubted, but their adverse effect profile is the subject of controversy, particularly the potential to cause venous thromboembolism. Two linked studies add to this debate (doi:10.1136/bmj.d2139; doi:10.1136/bmj.d2151).1 2 Both are observational database studies and produce remarkably similar results, which support another two studies published in the BMJ in 2009.3 4 All of these studies suggest that drospirenone increases the risk of venous thromboembolism compared with the progestogen, levonorgestrel. However, at least two other studies disagree.5 6

The two new papers analyse …

Get access to this article and all of bmj.com for the next 14 days

Sign up for a 14 day free trial today

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

Article access

Article access for 1 day

Purchase this article for £20 $30 €32*

The PDF version can be downloaded as your personal record

* Prices do not include VAT

THIS WEEK'S POLL